Skip to main content

Table 1 Patient characteristics, tumor classification and treatment of all patients with recurrent head and neck cancer

From: Ways to unravel the clinical potential of carbon ions for head and neck cancer reirradiation: dosimetric comparison and local failure pattern analysis as part of the prospective randomized CARE trial

Pat ReRT Age (y) KPS (%) Localization Type Concept T N M R G Interval (y) ReRT EQD2 (Gy) Cum. EQD2 (Gy) CTV (ccm)
01 CIRT 54 70 Oral cavity SCC Postop 4 0 0 2 2 1.0 75.0 129.0 167.9
02 CIRT 57 90 Nasopharynx SCC Def 2 0 0   2 0.7 63.8 137.8 30.6
03 CIRT 61 90 Hypopharynx SCC Def 4 0 0   3 3.6 63.8 123.8 84.0
04 VMAT 72 80 Sinuses SCC Def 4 0 0   2 1.0 60.0 126.0 110.0
05 CIRT 73 70 Oral cavity MEC Def 4 0 0   3 1.0 67.5 147.5 25.0
06 VMAT 71 80 Oropharynx SCC Def 4 0 0   2 7.2 60.0 123.0 65.0
07 VMAT 54 80 Nasopharynx SCC Def 1 2 0   3 4.5 60.0 124.0 54.7
08 CIRT 54 90 Sinuses AC Postop 3 0 0 2 3 1.6 67.5 127.5 49.3
09 VMAT 52 80 Skull base AC def 4 0 0   3 0.9 60.0 130.0 10.4
10 VMAT 49 80 Nasopharynx SCC def 4 0 0   3 3.3 60.0 124.0 31.7
11 VMAT 65 80 Nasal cavity SCC Def 3 0 0   3 4.0 60.0 130.0 37.4
12 VMAT 55 80 Nasal cavity SCC Postop 3 0 1 1 2 1.7 60.0 120.0 25.6
13 CIRT 62 70 Oral cavity SCC Def 3 0 0   2 8.3 63.8 137.8 42.4
14 CIRT 69 70 Oral cavity SCC Def 4 0 0   3 28.0 63.8 138.8 196.4
15 CIRT 50 90 Nasal cavity SCC Postop 4 0 0 2 3 1.2 63.8 129.8 139.6
16 CIRT 69 80 Oropharynx SCC Def 4 0 0   3 17.9 67.5 133.5 42.6
  1. CIRT carbon ion radiotherapy, VMAT volumetric modulated arc therapy, KPS Karnofsky Performance Score, EQD2 equivalent dose in 2 Gy fractions, ReRT re-radiotherapy, GTV gross tumor volume, CTV clinical target volume, PTV planning target volume, f female, m male, SCC squamous cell carcinoma, MEC mucoepidermoid carcinoma, AC adenocarcinoma